This is the first study to prospectively evaluate the combined use of radium-223 dichloride and a novel oral hormonal therapy, abiraterone acetate, in men with metastatic castration-resistant prostate cancer. The eRADicAte study showed that patients with metastatic castration-resistant prostate cancer experienced clinically meaningful improvements in quality of life with decreased pain, reduction in bone lesions, and an acceptable safety and toxicity profile. Background: Multiple castration-resistant prostate cancer (CRPC) therapies are approved by the United States Food and Drug Administration. Radium-223 dichloride (Ra-223) with abiraterone acetate plus prednisone have different mechanisms of action and distinct off-target side-effect profiles. We prospectively investigated their combined safety, tolerability, and patient-reported outcome measures. Patients and Methods: eRADicAte, an investigator-initiated, phase II trial, studied 31 patients with metastatic CRPC, from 5 United States uro-oncology research sites. Patients completed 6 cycles of Ra-223 with concurrent abiraterone therapy. Quality of life and pain were assessed using the Functional Assessment of Cancer Therapy-Prostate and the Brief Pain Inventory-Short Form questionnaires and their subscales; we reported the number of subjects meeting standardized criteria for clinically meaningful improvements on each scale. Safety assessment included Eastern Cooperative Oncology Group performance status, laboratory changes, opioid use, radiographic responses, and adverse events (AEs). Results: Twenty of 31 (65%) experienced positive clinically meaningful improvement changes on the Functional Assessment of Cancer TherapyProstate, and 25 (81%) of 31 on the Prostate Cancer Subscale. Eighteen (58%) of 31 demonstrated reduced pain intensity and 12 (39%) of 31 demonstrated reduction of pain interference in their lives. At baseline, subjects averaged 11.6 AE 2.8 bone lesions; at the end of treatment, subjects averaged 5.6 AE 2.4 bone lesions (P ¼ .0002). The most frequent AEs were diarrhea (17%), nausea (17%), and fatigue (14%). There were 6 serious AEs; 1 led to study withdrawal. Conclusions: Patients experienced clinically meaningful improvements in quality of life and pain, without unexpected adverse toxicities. Phase III combination trials of Ra-223 with novel oral hormonal agents are ongoing to further evaluate radiographic progression and overall survival benefit.
Introduction
Metastatic castration-resistant prostate cancer (mCRPC) is a terminal disease. Bone metastases have well-documented predilection in patients with advanced prostate cancer and thus may significantly impact quality of life (QOL) for these patients; symptoms may include bone pain, decreased performance status, and increased analgesic use. Since 2010, there are now 5 mCRPC life-prolonging therapeutic agents that have received United States Food and Drug Administration and European Medicines Agency approval. These therapies include sipuleucel-T, cabazitaxel, abiraterone acetate, enzalutamide, and radium-233 dichloride. [1] [2] [3] [4] [5] Nonetheless, their successive approval over a rapid timeline has not allowed for prospective evaluation of their combined uses. To our knowledge, we conducted the first study to prospectively evaluate the combined use of Ra-223 with abiraterone acetate (AA) plus prednisone in patients with symptomatic bone mCRPC.
Patients and Methods

Trial Design
eRADicAte is an investigator-initiated, prospective, phase II trial. The primary objective was to investigate the effects of concurrent treatment of Ra-223 and AA on QOL and bone pain. Five United States uro-oncology research sites accrued protocol appropriate patients with mCRPC. Patients had radiographically confirmed bone metastasis and Prostate Cancer Working Group 2 documentation of symptomatic bone pain requiring either palliative external beam radiation therapy and/or the need for analgesics. Enrolled patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. Exclusion criteria included the presence of malignant pleural effusion, or known lung, liver, or brain metastasis; previous treatment with AA for ! 90 days prior to enrollment; prior treatment with any radiopharmaceutical, or initiation of an antiresorptive medication for ! 90 days prior to enrollment; and cytotoxic chemotherapy within 4 weeks of enrollment.
Sterling Institutional Review Board (Atlanta, GA) oversaw the study. Each eligible candidate signed the approved Informed Consent Form prior to conducting any study-specific procedure or changes to study-specific medications. The study is registered on ClinicalTrials.gov, ID# NCT02097303.
Treatment Protocol
Enrolled patients initiated a daily dose of AA, 1000 mg, plus prednisone (5 mg twice a day) < 90 days prior to, or < 30 days after the first Ra-223 treatment. Patients had 6 intravenous infusions of Ra-223 (50 kBq/kg body weight), administered every 4 weeks for a course of 6 cycles. Bone scans were performed at baseline and end of treatment (EOT). Electrocardiogram and computed tomography (CT) scans were performed at baseline, cycle 4, and EOT. Questionnaires, ECOG, physical exam, skeletal-related event (SRE) assessment, disease progression assessment, medication review, and laboratory testing were performed at every visit.
Data Assessment Tools
The primary objective of the trial was to investigate the effects of concurrent treatment of Ra-223 and AA on quality-of-life and bone pain using the Functional Assessment of Cancer Therapy (FACT) questionnaires, the Brief Pain Inventory-Short Form (BPI-SF) questionnaires, and their subscales. [6] [7] [8] [9] The FACT-General (FACT-G) is a 28-item QOL measure that provides a total score as well as 5 subscale scores: Physical, Functional, Social, Emotional, Well-Being, and Satisfaction with Treatment. 6 Each question has 5 possible responses ranging from "None At All" ¼ 0 points, to "Very Much" ¼ 5 points. A higher score indicates a healthier response.
The FACT-P is a combination of the FACT-G with a 12-item Prostate Carcinoma subscale that contains items assessing symptoms/ problems related to prostate carcinoma and its treatment. The Treatment Outcome Index (FACT-TOI) is derived from the sum of the Physical Well-Being, Functional Well-Being, and Prostate Carcinoma subscale scores and is believed to be the most sensitive measure of patient-reported health. The Prostate Cancer, Pain-Related Subscale is calculated from the 4 questions on pain in the FACT-P Prostate Cancer Subscale.
The BPI was developed specifically as an instrument to assess cancer-related pain and pain interference. 8, 9 A series of scales ranging from 0 to 10 are used to assess pain at its most intense, at its least intense, on average, and at the time of the survey and to assess how pain interferes with several QOL domains, including activity levels, walking ability, mood, sleep, work, and relationships with others. Patients are also asked to estimate the degree of pain relief, indicate areas of pain on a schematic drawing, and estimate the percentage of pain owing to cancer-related versus nonecancerrelated causes. The BPI has strong evidence supporting its reliability and validity, has been used in a group-wide ECOG study that demonstrated its acceptability to patients and its feasibility in clinical trials, and has been adopted by the World Health Organization as a measure of cancer-related pain. 10 The BPI measures how much pain has interfered with 7 daily activities, including general activity, walking, work, mood, enjoyment of life, relations with others, and sleep. BPI pain interference is scored as the mean of the 7 interference items. 11 For pain relief, patients are asked how much pain relief their treatments or medications have provided and asked to rate as a % of relief, ranging from 0% relief to 100% pain relief. The FACT-P and BPI-SF and their subscales have prespecified criteria for the numeric change needed to identify a clinically meaningful improvement (CMI), an estimate of whether that patient has experienced a change (improvement) that is perceptible to him. Patients that have changes larger than the CMI values are considered to have experienced perceptible improvements. For FACT-P, CMI are taken from Cella et al and Harland et al 12, 13 and the FACT-P scoring guide. 7 For BPI-SF, CMI are taken from Logothetis et al. 14 The safety of the treatment was assessed by ECOG, review of pain medication, clinical laboratory results, and adverse events (AEs). This included the incidence and severity of AEs, serious AEs, and events leading to withdrawal. All events were coded using the standard Medical Dictionary for Regulatory Activities (MedDRA). 15 eRADicAte more on the ECOG scale. 19 Standard criteria were used to assess SREs, prostate-specific antigen (PSA) and alkaline phosphatase (ALP) levels, as well as a need for additional antineoplastic therapy.
Statistical Methodology
Continuous variables were summarized with descriptive statistics, including median and range, and confidence intervals (CIs); counts and percentages were used to summarize categorical variables. The Student t test compared the number of bone scan lesions and lab values at baseline and EOT. After the initial review of the data and based on the positive responses of the patients, post hoc analyses included the assessment of the frequency and percentage of patients achieving CMI in FACT-P, BPI-SF, and their subscales. [11] [12] [13] Efficacy data were evaluated using the per-protocol method on the 31 patients that completed baseline testing as well as all 6 Ra-223 cycles and EOT visit. Baseline and safety analyses were conducted on all 36 patients enrolled.
This phase II study was not powered to show statistical significance, but to collect data for the future design of a randomized control trial. Therefore, there are no hypothesis tests and no sample size calculations.
Results
Thirty-six patients met eligibility criteria and enrolled in the study from April 8, 2014 to July 13, 2015. Figure 1 shows the patient flow diagram from screening to EOT. Table 1 describes the demographics and baseline characteristics for enrolled patients.
Of the 36 patients enrolled, 31 received Ra-223 every 4 weeks for a total of 6 cycles and concurrent AA with prednisone for a minimum of 26 weeks and EOT visit 30 days after last dose of Ra-223 (Figure 1 ).
Figure 1 Patient Flow Diagram
Abbreviations: ECG ¼ electrocardiography; LTF ¼ lost to follow-up; RT ¼ radiotherapy; SAE ¼ severe adverse effects.
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These 31 patients comprise the primary efficacy population. Compliance was high, with all 31 patients providing all objective-required data.
Protocol allowed AA initiation up to 90 days prior to first dose of Ra-223. Median AA use before first Ra-223 dose was 80 days (95% CI, 59.137-100.863 days). One patient started Ra-223, 138 days after he started AA. This deviation was attributed to unavailability of the drug.
Three (8.3%) of 36 enrolled patients required dose reduction of AA; all of which were prompted by AEs. One patient experienced worsening fatigue, 1 experienced asymptomatic elevated hepatic enzymes, and 1 experienced elevated hepatic enzymes with associated Table 2 provides the number and percentage of patients with scores that met or exceeded QOL CMI criteria at any time. Table 3 provides the criteria for CMI for the pain subscales the number and percentage of patients demonstrating pain reduction.
QOL and Pain Assessments
Radiologic Assessment
The mean number of bone scan lesions at baseline was 11.6 AE 2.8. At EOT, the mean number of bone lesions decreased to 5.6 AE 2.4 (P ¼ .0002). Bone imaging response was assessed at baseline and at EOT visit. Twenty-nine (94%) of 31 had stable disease by EOT and 2 (6%) of 31 had progressed, which is defined as 2 or more additional lesions. 16 Determination of measurable disease progression or response was based on modified Response Evaluation Criteria in Solid Tumors criteria. At study entry, 8 (26%) of 31 had target lesions, and 31 (100%) of 31 patients had nontarget lesions. Eight (26%) of 31 patients showed a radiologic extraskeletal progression during the therapy, and 4 (13%) of 31 patients showed partial or complete response.
ALP and PSA
Baseline ALP was 261 AE 284 ng/dL; at EOT, it was 111.0 AE 187 ng/dL (P < .00001). Baseline PSA was 87 AE 223 ng/dL; at EOT, it was 137 AE 441 ng/dL (P ¼ .4870).
Safety
Overall, 30 (83%) of 36 patients reported 186 AEs; 179 (96%) of 186 were grade 1 or 2, of which 70 (39%) of 179 were treatmentrelated. This includes clinically significant laboratory abnormalities. The most frequent treatment-related events were diarrhea, nausea, and fatigue with 6 (17%) of 36, 6 (17%) of 36, and 5 (14%) of 36 reporting those, respectively.
Six serious AEs were reported, and only 1 was attributed to study medication. One patient died owing to cardiopulmonary arrest, unrelated to study medication. No patients progressed during the trial that required additional antineoplastic therapy.
Nearly one-half of all patients, 17 (47%) of 36, reported stable ECOG scores, 9 (25%) of 36 patients had a sustained or intermittent improvement of 1 point, and 8 (22%) of 36 patients worsened.
Sixteen (44.4%) of 36 patients reduced their use of pain medication during the study. Most patients (19 [52.3%] of 36) were stable in their medication use. Only 1 (2.8%) patient increased medication use during the study.
No SREs or progression to antineoplastic medications occurred during the study.
Discussion
To our knowledge, the eRADicAte trial is the first reported prospective trial of the combined use of Ra-223 and AA for patients with symptomatic bone mCRPC. Ra-223 is an alpha emitting-targeted therapy that selectively targets the bone microenvironment and bone metastatic tumor. Thus, combing Ra-223 may offer potentially a synergistic mechanism of action and therapeutic benefit with an ARtargeted therapy, AA. This small open-label phase II trial assessed QOL parameters, as reflected by the brief pain index and FACT-P eRADicAte questionnaires as well as evaluation for any AEs of interest when combining these novel therapies. This study was designed to use 2 treatment modalities, per approved product information labeling. The eRADicAte results demonstrated CMIs from the combined use of Ra-223 and AA and an acceptable safety and toxicity profile. If drug accessibility or costs for both CRPC agents were attainable, the combined use of Ra -223 and AA may have the potential to provide additional therapeutic and symptomatic benefits for patients with metastatic bone disease in mCRPC.
After obtaining baseline CT and bone scans before initiating combined drug treatment, neither a CT nor bone scan appears necessary until completion of Ra-223 (6 cycles) unless the patient has worsening and/or new symptomatologic progression or significantly worsening laboratory values. Physician-patient decisionmaking will supersede any rigid recommendation; however, recent US Expanded Access Program (EAP) and the Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) data supports the importance for patients to receive 5 to 6 cycles of Ra-223 to optimize its survival prolongation benefit. 20, 21 The primary limitations of this phase II study are: single-arm study; small sample size; study design allowed AA to be started up to 90 days prior to Ra-223 use, which made PSA evaluation variable; and the lack of long-term follow-up prevents any assessment for radiographic progression-free survival or overall survival.
Conclusions
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